Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Kessler

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
International Journal of Oncology|November 3, 2010
Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profileJohannes Dreischalück, Christian Schwöppe, Tilmann Spieker, et al.
Leukemia Research|May 3, 2015
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculatureNiklas Börschel, Christian Schwöppe, Caroline Zerbst, et al.
Radiology|June 15, 2007
Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in miceThorsten Persigehl, Ralf Bieker, Lars Matuszewski, et al.
British Journal of Haematology|June 9, 2020
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemiaMatthias Floeth, Sandra Elges, Joachim Gerss, et al.
Annals of Hematology|March 21, 2015
Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's diseaseLinus Angenendt, Andrea Kerkhoff, Stefanie Wiebe, et al.
Plos One|February 22, 2020
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcomaCaroline Brand, Burkhard Greve, Tobias Bölling, et al.
British Journal of Haematology|February 22, 2021
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantationChristoph Schliemann, Torsten Kessler, Andrew F Berdel, et al.
Cancers|July 2, 2021
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor InfarctionAndrew F Berdel, Christian Schwöppe, Caroline Brand, et al.
Leukemia & Lymphoma|March 29, 2021
Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancyDaniela V Wenge, Klaus Wethmar, Jan-Henrik Mikesch, et al.
Cancer|March 17, 2023
Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study GroupNicole Bodmer, Stefanie Hecker-Nolting, Godehard Friedel, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
International Journal of Oncology|November 3, 2010
Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profileJohannes Dreischalück, Christian Schwöppe, Tilmann Spieker, et al.
Leukemia Research|May 3, 2015
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculatureNiklas Börschel, Christian Schwöppe, Caroline Zerbst, et al.
Radiology|June 15, 2007
Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in miceThorsten Persigehl, Ralf Bieker, Lars Matuszewski, et al.
British Journal of Haematology|June 9, 2020
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemiaMatthias Floeth, Sandra Elges, Joachim Gerss, et al.
Annals of Hematology|March 21, 2015
Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's diseaseLinus Angenendt, Andrea Kerkhoff, Stefanie Wiebe, et al.
Plos One|February 22, 2020
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcomaCaroline Brand, Burkhard Greve, Tobias Bölling, et al.
British Journal of Haematology|February 22, 2021
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantationChristoph Schliemann, Torsten Kessler, Andrew F Berdel, et al.
Cancers|July 2, 2021
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor InfarctionAndrew F Berdel, Christian Schwöppe, Caroline Brand, et al.
Leukemia & Lymphoma|March 29, 2021
Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancyDaniela V Wenge, Klaus Wethmar, Jan-Henrik Mikesch, et al.
Cancer|March 17, 2023
Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study GroupNicole Bodmer, Stefanie Hecker-Nolting, Godehard Friedel, et al.
Pageof 8